Table of Contents
- Trial Overview
- Who Is Being Studied
- Trial Phases and Study Designs
- What the Trials Measure
- Treatment Combinations Being Tested
- How Safety Is Tracked
- What This Means for Patients
Trial Overview
The trial data shows three authorised studies of LUXDEGALUTAMIDE in advanced prostate cancer.[1][2][3] Two studies are Phase 2 and one is Phase 1.[1][2][3] Together, they look at whether the treatment combinations are safe, tolerable, and effective in adult men with metastatic prostate cancer.[1][2][3]
Who Is Being Studied
One study includes adult male patients with PSMA-positive metastatic castration resistant prostate cancer, which means the cancer has spread, still grows despite hormone-lowering treatment, and shows the PSMA marker.[1] Another study includes adult male patients with metastatic hormone-sensitive prostate cancer, meaning the cancer has spread but still responds to hormone-based treatment.[2] The Phase 1 study includes men with metastatic castrate resistant prostate cancer that has stopped responding to other treatments.[3]
These are not general prostate cancer studies for all patients.[1][2][3] Each trial focuses on a more specific group, so the study population is narrow and clearly defined.[1][2][3]
Trial Phases and Study Designs
The Phase 2 studies are interventional and randomized in at least one case, which means participants receive study treatments and may be assigned to different groups for comparison.[1][2] The Phase 1 study is also interventional and is designed to find recommended doses, check early safety, and explore early signs of response.[3]
In the Phase 1 study, the source data describes parts of the trial such as Part 1a, Part 1b, and Part 2.[3] This means the study is split into steps so researchers can first learn about dose and safety, then move to later testing of response.[3]
What the Trials Measure
The Phase 2 prostate cancer studies use PSA50 and PSA90 as key outcome measures.[1][2] PSA is a blood marker used in prostate cancer, and these outcomes check whether PSA falls by at least 50% or 90% from the starting level.[1][2] In one study, the PSA50 result must be confirmed by another PSA test at least 3 weeks later without cancer progression in between.[1] In the other study, the PSA90 result uses the same kind of confirmation rule.[2]
The Phase 1 study also measures dose-limiting toxicities, which are side effects serious enough to limit how much treatment can be given.[3] It also looks at PSA50 at Month 6 in later parts of the trial.[3]
Treatment Combinations Being Tested
One Phase 2 study tests LUXDEGALUTAMIDE with lutetium (177Lu) vipivotide tetraxetan, and the trial data also lists GOZETOTIDE and Pluvicto among the interventions.[1] The study summary says the goal is to determine the dose for Phase III and to compare the combination against the comparator treatment.[1]
Another Phase 2 study tests LUXDEGALUTAMIDE with abiraterone and compares doses or pooled doses against control treatment.[2] The trial summary says the study aims to choose the best dose and compare the combination with control in terms of efficacy, safety, and tolerability.[2]
The Phase 1 study tests LUXDEGALUTAMIDE with DZR123 and also mentions other prostate cancer treatments in the intervention list, including docetaxel, cabazitaxel, abiraterone, and enzalutamide.[3] The study summary says it is exploring recommended doses and early signs of activity for the combination.[3]
How Safety Is Tracked
All three studies track adverse events, which are unwanted medical problems that happen during treatment.[1][2][3] They also collect laboratory values, vital signs, and ECGs, which help researchers watch the body’s response to treatment and look for safety problems.[1][2][3]
The studies also measure tolerability, which means how well participants can stay on treatment without major problems such as dose interruptions, dose reductions, or stopping the study drug.[1][2][3] The Phase 1 study also tracks duration of exposure to each study drug.[3]
What This Means for Patients
For patients, these trials show that LUXDEGALUTAMIDE is being studied as part of combination treatment plans for advanced prostate cancer, not as a stand-alone general treatment for all cases.[1][2][3] The research is still focused on learning the best dose, checking safety, and seeing whether PSA levels improve in the target groups.[1][2][3]
Because the studies are authorised and have clearly defined groups, they are part of a structured research program for men with advanced prostate cancer.[1][2][3] The main question across the trials is whether these treatment combinations can give meaningful PSA responses while remaining safe and tolerable.[1][2][3]
